These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 9818072

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata.
    Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW.
    Biochemistry; 1996 Oct 15; 35(41):13303-9. PubMed ID: 8873596
    [Abstract] [Full Text] [Related]

  • 4. Preclinical and clinical results with the natural marine product ET-743.
    D'Incalci M, Jimeno J.
    Expert Opin Investig Drugs; 2003 Nov 15; 12(11):1843-53. PubMed ID: 14585059
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.
    Martinez EJ, Corey EJ, Owa T.
    Chem Biol; 2001 Dec 15; 8(12):1151-60. PubMed ID: 11755394
    [Abstract] [Full Text] [Related]

  • 7. Unique features of the mode of action of ET-743.
    D'Incalci M, Erba E, Damia G, Galliera E, Carrassa L, Marchini S, Mantovani R, Tognon G, Fruscio R, Jimeno J, Faircloth GT.
    Oncologist; 2002 Dec 15; 7(3):210-6. PubMed ID: 12065793
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.
    Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR.
    Clin Cancer Res; 2001 Oct 15; 7(10):3251-7. PubMed ID: 11595721
    [Abstract] [Full Text] [Related]

  • 12. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.
    Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, Olimpio CO, Bonardi C, Garbi A, Lissoni A, de Braud F, Jimeno J, D'Incalci M.
    Cancer Res; 2005 Apr 01; 65(7):2964-71. PubMed ID: 15805300
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.
    Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, D'Incalci M.
    Int J Cancer; 2001 May 15; 92(4):583-8. PubMed ID: 11304695
    [Abstract] [Full Text] [Related]

  • 15. Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743.
    Kanzaki A, Takebayashi Y, Ren XQ, Miyashita H, Mori S, Akiyama S, Pommier Y.
    Mol Cancer Ther; 2002 Dec 15; 1(14):1327-34. PubMed ID: 12516966
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
    Petit T, Izbicka E, Lawrence RA, Bishop WR, Weitman S, Von Hoff DD.
    Ann Oncol; 1999 Apr 15; 10(4):449-53. PubMed ID: 10370788
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.